

Application No. 09/778,187
RCE filed May 18, 2005

2. Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-19 (Cancelled)

20. (Previously presented) An isolated polypeptide comprising an amino acid sequence that is at least 90% identical to amino acids X_1 to X_2 as shown in SEQ ID NO: 2 wherein X_1 is 1 or 39 and X_2 is 374 or 442, said isolated polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.

21. (Previously presented) The isolated polypeptide according to Claim 20, wherein X_2 is 374.

22. (Previously presented) An isolated polypeptide selected from the group consisting of:
(a) a polypeptide comprising amino acids X_1 to X_2 as shown in SEQ ID NO: 2, wherein X_1 is 1 or 39 and X_2 is 374 or 442;
(b) a polypeptide comprising amino acids X_3 to X_4 as shown in SEQ ID NO: 4, wherein X_3 is 1 or 21 and X_4 is 356 or 423; and
(c) a polypeptide comprising a fragment of amino acids X_1 to X_2 in (a) or X_3 to X_4 in (b), said isolated polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.

23. (Previously presented) The isolated polypeptide according to Claim 22 comprising amino acids X_1 to X_2 as shown in SEQ ID NO: 2 or a fragment of said amino acids, wherein X_1 is 1 or 39 and X_2 is 374 or 442.

24. (Previously presented) The isolated polypeptide according to Claim 23 wherein X_2 is 374.

25. (Previously presented) The isolated polypeptide according to Claim 23 wherein X_2 is 442.

Application No. 09/778,187
RCE filed May 18, 2005

26. (Previously presented) The isolated polypeptide according to Claim 22 comprising amino acids X_3 to X_4 as shown in SEQ ID NO: 4 or a fragment of said amino acids, wherein X_3 is 1 or 21 and X_4 is 356 or 423.

27. (Previously presented) The isolated polypeptide according to Claim 26 wherein X_4 is 356.

28. (Previously presented) The isolated polypeptide according to Claim 26 wherein X_4 is 423.

29. (Previously presented) The isolated polypeptide according to Claim 24 or 27 that is soluble.

30. (Currently amended) A fusion polypeptide comprising the polypeptide according to Claim 2023.

31. (Currently amended) The fusion polypeptide according to Claim 30, wherein said fusion polypeptide comprises a Fc region, and/or a peptide linker, or a Fc region and a peptide linker.

32. (Currently amended) An oligomer comprising the polypeptide according to Claim 2023.

33. (Currently amended) The oligomer according to Claim 32 which is a dimer, a trimer, or a tetramer.

34. (Currently amended) A composition comprising the polypeptide according to Claim 2023 and a suitable carrier.

35. (Currently amended) An isolated polypeptide comprising an amino acid sequence encoded by a nucleic acid which is capable of hybridizing, under the following conditions: prewashing with 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0) and hybridizing at about 55 °C, 5

Application No. 09/778,187
RCE filed May 18, 2005

X SSC with an overnight incubation of moderate stringency, to the complement of SEQ ID NO: 1, from positions 130 to 1137, said isolated polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.

36. (Canceled)

37. (Previously presented) An isolated polypeptide comprising an amino acid sequence encoded by a nucleic acid selected from the group consisting of: (a) a nucleic acid comprising SEQ ID NO: 1; (b) a nucleic acid comprising SEQ ID NO: 1, from positions 16 or 130 to 1137; (c) a nucleic acid comprising SEQ ID NO: 3; (d) a nucleic acid comprising SEQ ID NO: 3, from positions 1 or 62 to 1069; and (e) a nucleic acid that is degenerate, as a result of the genetic code, to any of (a) to (d), said isolated polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.

38. (Previously presented) The isolated polypeptide according to Claim 37, wherein said amino acid sequence is encoded by a nucleic acid comprising SEQ ID NO: 1, from positions 16 or 130 to 1137, or, as a result of the genetic code, a nucleic acid degenerate thereto.

39. (Previously presented) The isolated polypeptide according to Claim 37, wherein said amino acid sequence is encoded by a nucleic acid comprising SEQ ID NO: 3, from positions 1 or 62 to 1069, or, as a result of the genetic code, a nucleic acid degenerate thereto.

40. (Previously presented) The isolated polypeptide according to Claim 38 which is soluble.

41. (Previously presented) A fusion polypeptide comprising the polypeptide according to Claim 38.

42. (Currently amended) The fusion polypeptide according to Claim 41, wherein said fusion polypeptide comprises a Fc region, and/or a peptide linker, or a Fc region and a peptide linker.

Application No. 09/778,187
RCE filed May 18, 2005

43. (Previously presented) An oligomer comprising the polypeptide according to Claim 38.

44. (Currently amended) The oligomer according to Claim 43 which is a dimer, a trimer, or a tetramer.

45. (Previously presented) A composition comprising the polypeptide according to Claim 38 and a suitable carrier.

46. (Currently amended) A polypeptide produced by a method comprising culturing a host cell transfected or transformed with a nucleic acid encoding said polypeptide under a condition such that said polypeptide is expressed from said nucleic acid, wherein said nucleic acid is capable of hybridizing, under the following conditions: prewashing with 5 X SSC, 0.5% SDS, 1.0 mM EDTA (ph 8.0) and hybridizing at about 55 °C, 5 X SSC with an overnight incubation of moderate stringency, to the complement of SEQ ID NO: 1, from positions 130 to 1137, said polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.

47. (Previously presented) The polypeptide according to Claim 46, wherein said method further comprises recovering said polypeptide.

48. (Previously presented) The polypeptide according to Claim 46, wherein said nucleic acid comprises a nucleotide sequence as shown in SEQ ID NO: 1, from positions 130 to 1137.

49. (Previously presented) The isolated polypeptide according to Claim 48 which is soluble.

50. (Previously presented) A fusion polypeptide comprising the polypeptide according to Claim 48.

Application No. 09/778,187
RCE filed May 18, 2005

51. (Currently amended) The fusion polypeptide according to Claim 50, wherein said fusion polypeptide comprises a Fc region, and/or a peptide linker, or a Fc region and a peptide linker.

52. (Previously presented) An oligomer comprising the polypeptide according to Claim 48.

53. (Currently amended) The oligomer according to Claim 52 which is a dimer, a trimer, or a tetramer.

54. (Previously presented) A composition comprising the polypeptide according to Claim 48 and a suitable carrier.

55 to 63. (Cancelled)